INK4a or the ARF-p53 pathway was not different from cases with retention of both pathways (5-year survival 45% vs 35%; P = 0.85), suggesting that selective inactivation of one of the pathways does not significantly influence overall survival. By contrast, the 5-year survival was only 7% for cases with concurrent disruption of p16
Introduction
Non-Hodgkin's lymphoma (NHL) encompasses a broad spectrum of tumors derived from cells of the lymphoid system. Tumors are usually assigned to one of several subtypes on the basis of clinical, immunophenotypical, genetic, and morphological properties. 1 Although combination chemotherapy has dramatically improved the overall prognosis in patients with aggressive NHL, marked individual differences in response to treatment still exist within and between different subtypes. Several phenotypic factors have been reported to influence the outcome, including age, tumor stage, performance status, tumor size, tumor burden, serum lactate dehydrogenase concentration (S-LDH), and number of involved extranodal disease sites. 2 Unraveling the biological background for these clinical prognostic factors may eventually form the basis for designing and implementing more differentiated therapeutic regimens.
Alterations of several oncogenes and tumor suppressor genes have been demonstrated in NHL. 3 As in many other types of cancer, the most commonly altered targets reported in NHL are the genes encoding the tumor suppressors p16 INK4a and p53. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] These proteins are key components of the machinery that controls cell cycle progression. 23, 24 p16
INK4a exerts a tumor-suppressive function by specifically interfering with the catalytic activity of complexes between cyclin D and cyclin-dependent kinase 4 (CDK4) or CDK6. 25 This inhibitory effect on cyclin D/CDK4(6) complexes prevents phosphorylation of the retinoblastoma protein (Rb) and the subsequent release of transcription factors that are required for passage into and through S phase, in particular members of the E2F transcription factor family. Another potent CDK inhibitor, p21 WAF1/CIP1 , is a downstream effector of p53 and controls cell cycle progression by inhibiting the activity of a broader range of CDKs. [26] [27] [28] Genetic and epigenetic alterations of p16 INK4a and p53 have been found in several subtypes of NHL, in particular in the progressed variants, yet little is known about their prognostic significance. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] A single study has demonstrated poor prognosis in cases with deletions or rearrangements of p16 INK4a , 21 and p53 mutations have been associated with adverse outcome in aggressive lymphomas. 10, 13 Recently, a novel putative tumor suppressor, ARF (human p14 ARF and murine p19 ARF ), was identified that may provide an important link between p53 and the p16
INK4a -Rb pathway. 29, 30 Expression of ARF, which is induced by hyperproliferative stimuli like the Myc and E1A oncogenes 31, 32 but not by DNA damage, 33, 34 results in apoptosis or cell growth arrest in both G 1 and G 2 . 33, 35 ARF and p16 INK4a are encoded by a single genetic locus, designated INK4a/ARF and located at chromosome 9p21. [35] [36] [37] [38] This locus consists of exon 1␤ specific for ARF, exon 1␣ specific for p16 INK4a , and exons 2 and 3 common to both genes ( Figure 1 ). Despite the extensive overlap at the gene level, ARF and p16
INK4a share no amino acid homology and possess distinct biochemical and regulatory properties. Recent work has shown that the tumor-suppressive functions of ARF may be ascribed to its ability to inhibit MDM2-mediated degradation of p53 in a feedback loop where p53 upregulates its inhibitor, MDM2, and downregulates its activator, ARF. 34, [39] [40] [41] Specifically, ARF binds to MDM2 and sequesters it into the nucleolus, thereby preventing it from degrading p53 in the nucleoplasm. [42] [43] [44] The existence of this delicate molecular circuitry suggests that loss of ARF function may be functionally equivalent to mutation of p53. This notion is reinforced by the observations that mice lacking ARF exon 1␤, but retaining functional p16
INK4a ,
Figure 1
Diagramatic representation of the INK4a/ARF locus, the transcripts encoded by this locus, and the molecular pathways in which they participate. ARF (p14 ARF ) is encoded by exons 1␤ and 2 and blocks MDM2-induced p53 degradation. p16
INK4a is encoded by exons 1␣, 2 and 3 and inhibits CDK4(6), which in turn prevents cells with functional Rb from entering S phase. develop tumors that are broadly similar to those reported in mice lacking p53, 33, 45 and that continuously growing mouse embryo fibroblast (MEF) cell lines usually harbor either ARF or p53 loss of function. 33 The possible role of ARF in the development of human cancers is, however, largely unknown. Evidence for selective deletion of exon 1␤ has been demonstrated only in a few cases of melanoma and T cell acute lymphoblastic leukemia. 46, 47 Moreover, inactivation of ARF by hypermethylation or mutation of exon 1␤ is rare in human tumors, 36, 37, [48] [49] [50] [51] including NHL. 52 Here, we demonstrate that single disruption of either p16
INK4a or the ARF-p53 pathway does not significantly influence the outcome of treatment in aggressive NHL, whereas concomitant disruption of both pathways is associated with shortened survival and is an independent negative prognostic factor.
Patients and methods

Patients and tissue samples
A total of 123 newly diagnosed NHLs referred to the Departments of Hematology at Herlev Hospital, Rigshospitalet and Odense University Hospital, Denmark, during the period 1984-1994 were included in this study. Routinely processed histological samples were available from all patients. Specimens were stained with hematoxylin-eosin and examined by immunohistology as described, 53 and then classified according to the Revised European-American Lymphoma (REAL) classification. 1 The following histological subtypes were included: DLC-B (n = 68); follicle center cell lymphoma (FCC) (n = 24); mucosa-associated lymphoid tissue (MALT)-type lymphoma (n = 2); immunocytoma (n = 2); mantle cell lymphoma (MCL) (n = 4); Burkitt's lymphoma (n = 3); peripheral T cell lymphoma (PTL), unspecified (n = 16); angioimmunoblastic T cell lymphoma (AILD) (n = 3); and T cell chronic lymphocytic leukemia (T-CLL) (n = 1). In all cases, frozen tissue blocks were also available. These samples had been frozen immediately after surgery in either liquid N 2 or a mixture of 2-methyl butane and dry ice and stored at −80°C until use. Clinical data were obtained retrospectively from the patient files. All patients were treated according to standard regimens. Almost all aggressive tumors were treated with combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Some of the cases had previously been examined for aberrations of ARF, p53 and p16 INK4a . 12 Approval of the study was obtained from the local ethical committee.
DNA isolation and deletion analysis
DNA was extracted from frozen tissue sections by proteinase K digestion and phenol-chloroform extraction, according to standard procedures, or by using the Puregene DNA Isolation Kit (Gentra Systems, Minneapolis, MN, USA). Deletions of the INK4a/ARF locus were detected by semi-quantitative duplex PCR, essentially as described. 53 Oligonucleotide primers for INK4a/ARF exons 1␤, 1␣ and 2 and for the internal control sequence (STS) on chromosome 9q were as described. 46, 54, 55 PCR was performed with the GeneAmp PCR System 9600 (Perkin-Elmer Cetus, Emeryville, CA, USA) and was maintained within the exponential range (20-24 cycles). ␣-33 P dATP was included in all reactions for labeling. The amplification products were separated on a 2% agarose gel, which was subsequently dried, exposed to a Storage Phosphor Screen (Molecular Dynamics, Sunnyvale, CA, USA) and inspected using the ImageQuant software (Molecular Dynamics). A case was considered to harbor deletion when the ratio of target sequence to reference sequence was less than 0.2 of that observed in DNA from healthy individuals, and when the results were reproducible in at least three independent experiments. DNA from the DOHH2 lymphoma cell line, which sustains homozygous deletion of the INK4a/ARF locus, 6 was used as positive control when mixed with normal control DNA.
Methylation-specific PCR (MSP) and bisulfite denaturing gradient gel electrophoresis (DGGE)
Methylation of the CpG island in the promoter region of the p16 INK4a gene 56 was characterized by MSP 57 and bisulfite-DGGE. 58 Both methods are based on initial treatment of genomic DNA with sodium bisulfite to convert unmethylated cytosine to uracil. 59 The bisulfite reaction was performed essentially as described. 60 Briefly, approximately 1 g of genomic DNA was denatured in 0.3 mol/l NaOH, followed by the addition of sodium bisulfite (Sigma Chemical, St Louis, MO, USA) to a final concentration of 3.1 mol/l, and hydroquinone (Sigma Chemical) to a final concentration of 2.5 mmol/l. After incubation at 55°C for 16 h, the DNA was recovered by using the GeneClean II Kit (Bio 101, Vista, CA, USA), desulfonated in 0.3 mol/l NaOH, and ethanol-precipitated. For MSP, two sets of primers 57 were used to selectively amplify methylated and unmethylated alleles, respectively. PCR was performed in volumes of 25 l, containing 1 × PCR buffer (10 mmol/l Tris-HCl (pH 8.3), 50 mmol/l KCl, 1.5 mmol/l MgCl 2 , 0.002% gelatin), 0.2 mmol/l cresol red, 12% sucrose, 10 pmol/l of each primer, 100 mol/l each dNTP, approximately 100 ng of DNA, and 0.8 units of AmpliTaq polymerase (Perkin-Elmer Cetus). The reaction was hotstarted, followed by 40 cycles at 94°C for 20 s, 60°C for 20 s, and 72°C for 30 s. Amplification products were analyzed in a 2% agarose gel. For bisulfite-DGGE, a set of previously described primers 58 was used to collectively amplify methylated and unmethylated alleles. PCR was performed as described, 58 using the Expand High Fidelity System (Boehringer-Mannheim, Mannheim, Germany). The 'GCclamped' PCR products were analyzed in a 6% polyacrylamide/10-60% denaturing gradient gel (100% denaturant = 7 mol/l urea and 40% formamide). 61 The gel was run at 160 V for 4 h in 1 × TAE buffer kept at a constant temperature of 54°C, stained with ethidium bromide, and photographed under UV transillumination.
Mutation detection and direct sequencing
Exons 2-11 of the p53 gene were scanned for mutations by PCR in combination with DGGE, using the primers and electrophoresis conditions described in a previous report. 62 Exons 1␤, 1␣, 2 and 3 of the INK4a/ARF locus were examined for mutations by PCR in combination with single-stranded conformation polymorphism (SSCP) analysis, using previously described primers. 46, 55 Abnormal DGGE and SSCP bands were excised from the gels, and their DNA was eluted in water, reamplified, and sequenced using a 
Statistical methods
Probability of survival was estimated according to the method of Kaplan and Meier 63 from date of diagnosis to death or last follow-up. Last follow-up was January 1998. The median follow-up time of patients alive (n = 26) was 107 months (range 28-147). The equality between survival curves was tested with the log rank test. The simultaneous relationships of multiple prognostic factors to survival were assessed using Cox's proportional hazard model. 64 Variables that met the 0.10 significance criteria in the univariate analysis were included in the multivariate analysis using forward selection. P values less than 0.05 were considered significant. All analyses were performed using the SAS software (Statistical Analysis System Institute, Cary, NC, USA).
Results
Deletions of the INK4a/ARF locus
Exons 1␤, 1␣ and 2 of the INK4a/ARF locus were examined for deletions by semi-quantitative duplex PCR analysis of genomic DNA from the group of 123 NHLs. Homozygous deletions were detected in three of 36 (8%) low-to intermediate-grade lymphomas and in 12 of 87 (14%) high-grade lymphomas. Exon 1␤ was selectively deleted in two DLC-Bs (3%), deletion of exon 2 alone was detected in one MCL (25%) and one DLC-B (1.5%), and the remaining 11 cases harbored deletion of all three exons. These included one of 24 FCCs (4%), one of four MCLs (25%), six of 68 DLC-Bs (9%), one of three Burkitt's lymphomas (33%), and two of 16 PTLs, unspecified (13%) ( Table 1) .
p16
INK4a promoter hypermethylation
The methylation status of a 150-bp region of the p16 INK4a promoter was examined by PCR analysis of bisulfite-reacted DNA (MSP 57 ), using primers designed to specifically amplify methylated alleles. Hypermethylation was detected in two of 36 (6%) low-to intermediate-grade lymphomas, including one of two MALT lymphomas (50%) and one of 24 FCCs (4%). ThirLeukemia teen of 87 high-grade tumors (15%) showed p16
INK4a hypermethylation, including 11 of 68 DLC-Bs (16%), one of three Burkitt's lymphomas (33%), and one of 16 PTLs, unspecified (6%) ( Table 1) .
We have recently demonstrated that methylation of another CDK inhibitor, p15 INK4b , can be detected in a small fraction of lymphocytes from normal blood by using the highly sensitive MSP method. 65 To exclude that positive MSP signals for p16
INK4a methylation in NHLs were due to such background amplification, we further evaluated the samples by the newly developed bisulfite-DGGE method. 58, 65 This method separates methylated alleles from their unmethylated counterparts after bisulfite treatment because of differences in thermal stability, which forms the basis for quantitating and isolating clonotypic epigenotypes present in complex cell populations. For all NHLs tested positive for p16
INK4a methylation by MSP, a distinct band was observed in the denaturing gradient gel at a position corresponding to the migration distance of fully methylated p16
INK4a alleles from cell lines with known methylation status (Figure 2a ). The intensities of the methylated bands were comparable to those of the unmethylated bands from the same samples, suggesting that a large proportion of cells in the tumors sustained p16
INK4a methylation. Sequence analysis of bands excised from the gel confirmed that all CpG sites of the target sequence were methylated (Figure 2b) .
Mutations of the p16 INK4a , ARF and p53 genes
Analysis of all exons and exon-intron boundaries of the INK4a/ARF locus by PCR/SSCP analysis revealed no point or frameshift mutations in the 123 NHLs. The same samples were subjected to systematic PCR/DGGE-based scanning of exons 2-11 and all splice sites of the p53 gene (Figure 3a) . Enrichment and direct sequence analysis of DNA from bands with an altered mobility led to the identification of mutations in three of 36 (8%) low-to intermediate-grade cases, including one of four MCLs (25%) and two of 24 FCCs (8%). Among the high-grade cases, 17 of 87 (20%) showed mutations, including 14 of 68 DLC-Bs (21%), two of three Burkitt's lymphomas (66%), and one of 16 PTLs, unspecified (6%) ( Table  1 ). The mutations included 18 missense mutations within exons 5-8, one G to A transition at position −1 of the acceptor splice site at the intron 4/exon 5 boundary, and one 19-bp frameshift deletion in exon 5. Three residues, P151, R248 and R273, were found to be altered in two, four and three of the samples, respectively. This is in keeping with previous observations that these sites are mutation hot spots in lymphomas and other human cancers. 66, 67 One of the missense variants, I254N, was due to a tandem mutation (TC to AT) (Figure 3b ). To prove that the two base changes occurred in cis, individual alleles were recovered from the denaturing gradient gel and sequenced (data not shown).
Correlations among aberrations of the p16
INK4a , ARF and p53 genes
The distribution of p16 INK4a , ARF and p53 aberrations among individual NHL cases is given in Table 1 . One or more of these genes were altered in 42 of 123 cases (34%), including 35 of 87 aggressive lymphomas (40%). There was no difference between the frequencies of these aberrations in B and T cell lymphomas (P = 0.14). Our data suggest a positive selection for tumor cells with aberrations of both p16
INK4a and the ARF-p53 pathway. Both concomitant p53 mutation and p16 INK4a methylation (P = 0.02; chi-square test) and concomitant p53 mutation and deletion of INK4a/ARF exon 2 (P = 0.01) occurred at significantly higher frequencies than expected. By contrast, the frequency of concurrent mutation of p53 and deletion of the entire INK4a/ARF locus was not higher than expected (P = 0.87).
Survival in relation to status of the p16 INK4a , ARF and p53 genes in aggressive lymphomas
On the basis of the observed status of the p16 INK4a , ARF and p53 genes and the molecular pathways in which the individual genes participate (cf. Figure 1) , each of the 87 patients with aggressive lymphoma histology (DLC-B, Burkitt's lymphoma, or PTL, unspecified) was assigned to one of four groups: (1) cases sustaining inactivation of the p16
INK4a pathway by hypermethylation of the p16
INK4a gene with no concomitant alterations of the ARF and p53 genes (n = 8); (2) cases with disruption of the ARF-p53 pathway by mutations in the p53 gene (n = 10) or selective deletion of INK4a/ARF exon 1␤ (n = 2) and apparent retention of p16 INK4a ; (3) cases sustaining dual pathway disruption, either by deletion of the entire INK4a/ARF locus (n = 8), concomitant deletion of INK4a/ARF exon 2 and p53 mutation (n = 2), or concurrent p16
INK4a hypermethylation and p53 mutation (n = 5); and (4) cases with no detectable aberrations of the three genes (n = 52).
According to the Kaplan-Meier estimates, the survival of the eight cases with selective inactivation of p16
INK4a by hypermethylation was not statistically different from that of the 12 cases with either p53 mutation or selective deletion of INK4a/ARF exon 1␤ (5-year survival 50% vs 42%; P = 0.78). Furthermore, no difference in survival was observed between these 20 cases harboring aberrations of either p16 INK4a or the p53-ARF pathway and the 52 cases with apparent retention of all three genes (5-year survival 45% vs 35%; P = 0.85), suggesting that selective inactivation of one of these pathways does not significantly influence overall survival (Figure 4) . By contrast, the Kaplan-Meier estimate of survival was significantly lower for the 15 patients with concomitant loss of p16 INK4a and the ARF-p53 pathway than for those with reten-
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Figure 4
Kaplan-Meier curves for overall survival for patients with aggressive tumors harboring concurrent disruption of p16
INK4a and the ARF-p53 pathway (dotted line; n = 15), hypermethylation of p16
INK4a
, deletion of INK4a/ARF exon 1␤ or mutation of p53 (dashed line; n = 20), or apparent retention of all three genes (solid line; n = 52).
Figure 5
Kaplan-Meier curves for overall survival for patients with DLC-B lymphomas with concurrent disruption of p16 INK4a and the ARF-p53 pathway (dotted line; n = 10), hypermethylation of p16 INK4a or selective abrogation of the ARF-p53 pathway (dashed line; n = 16), or apparent retention of all three genes (solid line; n = 42). tion of one or both pathways (5-year survival 7% vs 38%; P = 0.005). Specifically, the five patients with tumors harboring targeted alterations of p16 INK4a and p53 died 1, 3, 6, 9 and 14 months after diagnosis, respectively. Similarly, Kaplan-Meier curves for overall survival of patients with lymphomas of the single largest histological subtype, DLC-B, showed that patients with disruption of both pathways had a significantly shorter survival than patients with disruption of one or no pathways (P = 0.019) ( Figure 5 ). Even within the group of cases with low-to intermediate-grade histology, all cases with disruption of both pathways died within the first year from diagnosis.
The clinical and histological features of patients with aggressive lymphomas grouped according to the status of p16 INK4a and the ARF-p53 pathway are given in Table 2 . Univariate survival analysis including factors from the international prognostic index showed that age, clinical stage, dual p16
INK4a
and ARF-p53 pathway disruption, and elevated S-LDH were adverse prognostic factors. On stepwise multivariate regression analysis, age, dual p16
INK4a and ARF-p53 pathway disruption, and clinical stage retained independent prognostic significance for survival, while elevated S-LDH reached borderline significance (Table 3) . 
Discussion
Mounting evidence exists that cancer-related genes participate in pathways that control a wide range of cellular functions, and that genetic aberrations along the same pathways may be functionally equivalent. Considering molecular pathways rather than single genes may, therefore, dramatically increase the diagnostic and prognostic value of molecular analyses in cancer. In the present study, we have examined the status of p16 INK4a , ARF, and p53 in 123 cases of NHL at diagnosis and, in accordance with current knowledge about the molecular pathways in which these tumor suppressors participate, correlated these results with histology and survival.
In agreement with previous studies, 68 has demonstrated that ARF protein is absent in some human hematopoietic cell lines that abundantly express the ARF transcript. Whether disruption of the ARF-p53 pathway by post-transcriptional inactivation of ARF is a frequent event in lymphoid tumors will be subject to future studies.
One case of DLC-B showed concomitant deletion of the entire INK4a/ARF locus and mutation of the p53 gene. This finding corroborates previous observations in human tumor specimens 69 and cell lines 34, 50 that inactivation of ARF and p53 may not always be mutually exclusive. As proposed by Stott et al, 34 concurrent deletion of ARF and mutation of p53 may be a simple reflection of the order of events during tumor progression. If deletion of the region encompassing the INK4a/ARF locus on 9p21 occurs early in tumorigenesis, there would be little selection against p53. Conversely, if p53 mutation is an early event, a strong selection pressure would still exist against p16 INK4a , which could result in the coincidental co-deletion of ARF. INK4a by hypermethylation is a reversible process that may be influenced by conventional combination chemotherapy, a more likely explanation for the observed discrepancy in survival between p16
INK4a deficient vs p16 INK4a -and ARFdeficient cases is that ARF directly inhibits lymphomagenesis. This hypothesis is supported by previous observations that mice selectively inactivated for ARF are prone to developing lymphomas, 33 and that INK4a/ARF exon 1␤ is selectively deleted in a small fraction of chemically induced murine lymphomas. 70 The association of INK4a/ARF deletions with adverse prognosis in NHL is in agreement with the results reported by Garcia-Sanz et al, 21 who found a median survival of 10 months among seven cases with deletions or rearrangements of INK4a/ARF. Furthermore, a recent study of superficial bladder cancer showed that deletion of the INK4a/ARF locus, but not hypermethylation of p16
INK4a
, is correlated with poor prognosis. 71 Our data suggest the existence of an intimate relationship between p16
INK4a and the ARF-p53 pathway in the control of lymphoproliferation. The finding that selective disruption of INK4a or the ARF-p53 pathway does not significantly influence the outcome of treatment in aggressive NHL suggests the existence of a circuitry in which disruption of one of the pathways elicits a compensatory response from the retained pathway. This notion was reinforced by recent work delineating how loss of Rb function may trigger a biochemical fail-safe mechanism to protect against deregulated cell growth. According to the proposed model, loss of functional Rb results in deregulation of the E2F-1 transcription factor, which in turn causes stabilization of p53, 72, 73 probably by activating the transcription of ARF. 74 A similar, as yet unknown, mechanism may be elicited from the p16 INK4a -Rb pathway that compensates for the selective loss of functional p53.
Our study may have certain limitations. First, not all known components of the p16 INK4a and ARF-p53 pathways were examined. Even though genetic alterations of many of these components are considered to be rare in NHL, including mutation and deletion of the RB1 gene 75 and hypermethylation of ARF, 52 their inclusion might have improved the significance of our results. Second, deletions of regions at 9p21 in NHL may encompass more than 500 kb and eliminate several genes in addition to ARF and p16 INK4a , including the gene encoding the cyclin-dependent kinase inhibitor p15
INK4b , the interferon gene cluster, and the methylthioadenosine phosphorylase (MTAP) gene. 76 Therefore, we cannot unambiguously ascribe a particular phenotype to the specific loss of the INK4a/ARF locus. However, the five patients with tumors harboring targeted alterations of p16 INK4a and p53 all died shortly after diagnosis (1, 3, 6, 9 and 14 months, respectively), and hence exhibit a clinical course similar to patients with tumors harboring INK4a/ARF deletions, strongly implicating these tumor suppressors and their respective pathways in the control of lymphoproliferation.
In conclusion, we have shown that virtually all patients with dual disruption of p16
INK4a and the ARF-p53 pathway die within the first year of diagnosis, irrespective of histological subtype, while selective inactivation of either pathway does not influence overall survival. These data suggest that p16
and ARF-p53 mediate two cellular pathways that individually suppress lymphoid tumorigenesis and monitor loss of each other in a compensatory fashion. The identification of patients with tumors harboring abrogation of both pathways may identify subgroups of patients who are refractory to conventional therapy and who may therefore be candidates for alternative regimens. Whether the inclusion of possible alterations of the remaining components of the same pathways, including MDM2, CDK4, cyclin D1, E2F-1 and Rb, will further improve the diagnostic and prognostic information is a subject for further studies.
